Title: The role of interleukin-17 in the pathogenesis and treatment of severe neutrophilic asthma

Abstract:

Asthma is a common chronic airway disease affecting approximately 334 million people worldwide, and about 7 million children globally. Approximately 10% of patients with asthma have severe refractory disease, which is difficult to control on high dose inhaled corticosteroids and long-acting β2-agonists (LABA). Half of these patients have neutrophilic asthma. Neutrophilic asthma is a phenotype of asthma characterized by severe and persistent airflow obstruction, frequent exacerbations and hospitalization, and is associated with status asthmaticus, and fatal asthma. Immunopathologically, it is characterized by the presence of high levels of neutrophils in the lungs and airways. Interleukin-17 secreted by Th17 cells, plays a key role in the pathogenesis of neutrophilic asthma by expressing the secretion of chemoattractant cytokines and chemokines, such as IL-8 for the recruitment and activation of neutrophils. Activated neutrophils produce an oxidative burst, releasing multiple proteinases, reactive oxygen species, and cytokines which cause airway epithelial cell injury, inflammation, airway hyperresponsiveness, and remodeling. Most patients with neutrophilic asthma are unresponsive to high dose inhaled corticosteroids, and to eosinophilic asthma targeted biologics, such as omalizumab (anti-IgE), mepolizumab, reslizumab (anti-IL-5), benralizumab (anti-IL-5R), dupilumab (anti-IL-4Rα), tezepelumab (anti-TSLP). Blockage of IL-17 with monoclonal antibodies has not been successful in the precision treatment of neutrophilic asthma. Brodalumab, a monoclonal antibody against the IL-17 receptor did not meet end point in clinical trials. Similarly, blockade of IL-8 receptor CXCR2 produced minimum asthma control. Treatment of neutrophilic asthma is challenging. The most appropriate approach is to use single inhaler tripple therapy incorporating a long-acting muscarinic antagonist; and macrolide antibiotics, such as azithromycin. Accompanying airway remodeling and airway muscle hyperplasia and hypertrophy may require bronchial thermoplasty (BT). This bronchoscopic therapy is effective in patients with severe, uncontrolled asthma irrespective of the phenotype. BT has been shown to reduce the severity of asthma symptoms, exacerbations, and to improve lung function, and health-related quality of life. BT has also a corticosteroid-sparing effect and can allow patients to wean from glucocorticoids.

Biography:

Nightingale Syabbalo is a Pulmonologist, and Clinical Respiratory Physiologist by training, and obtained his postgraduate training at St. George’s Hospital Medical School, University of London, UK. He was trained by one of the international distinguished Respirologists of our times. Nightingale has worked as an academician, Consultant Physician, and Clinical Researcher in several counties, including Canada, Kuwait, Oman, South Africa, and Zambia. He has published extensively in high-impact medical journals, and is an Editorial Board member of twenty-two journals in Pulmonology and Respiratory Medicine; and a reviewer of four journals in Thoracic Medicine, Respiratory Research, and Internal Medicine. Prof. Syabbalo’s current area of research focuses on the role of interleukins in the pathophysiology and treatment of severe asthma. He has also interested in the mechanisms of interleukins-1β in the pathogenesis and treatment of pericardial syndromes.